Clinical trials: Gemcitabine
Pancreatic Cancer
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
This phase II clinical trial studies the safety and effect of as second-line treatmen in local advanced or metastatic pancreatic cancer. The Gimatecan will be given every four weeks.
- Trial name
- NCT04571489
- Testing
- Gimatecan, tegafur, gimeracil and oteracil potassium, gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Lee's Pharmaceutical Limited
Biliary Tract Neoplasms
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
- Trial name
- TOPAZ-1 (NCT03875235)
- Testing
- Durvalumab
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 810 people
- Sponsor
- AstraZeneca
Locally Advanced Pancreatic Cancer
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
- Trial name
- TIGeR-PaC (NCT03257033)
- Testing
- Gemcitabine, nab-paclitaxel, RenovoCath
- Where
- 31 sites in United States, Belgium
- Volunteers
- 190 people
- Sponsor
- RenovoRx
Serous Ovarian Cancer, Advanced Ovarian Cancer
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.
- Trial name
- NCT06055348
- Testing
- SC0191, Gemcitabine, Paclitaxel
- Volunteers
- 112 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Locally Advanced Pancreatic Adenocarcinoma
Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel.
- Trial name
- PANOVA-3CA (NCT07319910)
- Testing
- TTFields, Gemcitabine, Nab paclitaxel
- Sponsor
- NovoCure GmbH
Advanced Endometrial Cancer, Sarcoma of Uterus
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
This clinical study plans to enroll 69 endometrial cancer patients and 5-10 uterine sarcoma patients. The trial is divided into a lead-in phase and a main phase.
- Trial name
- NCT05481645
- Testing
- TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection
- Where
- 11 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Untreated, Advanced Pancreatic Cancer
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.
Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer.
- Trial name
- NUMANTIA-2 (NCT07578337)
- Testing
- Gemcitabine (1000 mg/m2), Nab-paclitaxel (Abraxane), NLM-001
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Nelum Corp
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
NSCLC
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR mutations.
- Trial name
- NCT05493501
- Testing
- Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- EQRx International, Inc.
Non-small Cell Lung Cancer (NSCLC)
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)
- Trial name
- NCT07141563
- Testing
- Nivolumab + platinum-based chemotherapy
- Where
- Argentina
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of…
- Trial name
- NCT04974398
- Testing
- Penpulimab
- Where
- 56 sites in United States, Australia and 3 more
- Volunteers
- 296 people
- Sponsor
- Akeso
NMIBC
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with…
- Trial name
- NCT07424287
- Testing
- SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 236 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC)
A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H.
- Trial name
- NCT07804056
- Testing
- Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Hamlet Pharma AB
Lung Cancer, Non-Small Cell
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen(OTR) of pazopanib in combination with gemcitabine (Arm A) or pazopanib…
- Trial name
- NCT00678977
- Testing
- Pazopanib (GW786034), Gemcitabine, Cisplatin
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Genital Neoplasms, Female, Fallopian Tube Neoplasms
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment.
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00191607
- Testing
- Gemcitabine, liposomal doxorubicin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Breast Cancer
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended…
- Trial name
- NCT06775236
- Testing
- SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tablets
- Volunteers
- 410 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Pancreatic Cancer
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in…
- Trial name
- NCT06119217
- Testing
- TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 194 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Solid Tumor
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.
- Trial name
- NCT04934514
- Testing
- IAH0968, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 97 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Solid Tumors, Colorectal Cancer
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
- Trial name
- NCT05116891
- Testing
- CAN04 (nadunolimab), mFOLFOX, DTX
- Where
- 6 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- Cantargia AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.